StockNews.com initiated coverage on shares of Acorda Therapeutics (NASDAQ:ACOR – Free Report) in a research report sent to investors on Sunday. The firm issued a buy rating on the biopharmaceutical company’s stock.
Acorda Therapeutics Price Performance
The firm has a market capitalization of $820,000.00, a price-to-earnings ratio of 0.00 and a beta of 1.40. The company has a debt-to-equity ratio of 3.07, a current ratio of 0.33 and a quick ratio of 0.26. Acorda Therapeutics has a 52-week low of $0.61 and a 52-week high of $24.20. The business has a 50-day simple moving average of $10.85 and a 200-day simple moving average of $12.06.
About Acorda Therapeutics
Featured Stories
- Five stocks we like better than Acorda Therapeutics
- Ride Out The Recession With These Dividend KingsĀ
- NXP Semiconductors Will Set a New High Soon: $300 in Sight
- Stock Average Calculator
- Hilton Demonstrates Asset Light is Right for Investors
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- Boston Scientific Bucks the Medtech Slow Down and Raises Outlook
Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.